职称：副教授

学历：博士

邮箱：[email protected]

研究方向：T细胞自身免疫发生机制；抗体工程与细胞免疫治疗研究

学习、工作经历：

2011.9-2015.6中南民族大学生物技术学士

2015.9-2020.12华中农业大学生命科学技术体育投注平台 生物化学与分子生物学博士

2020.12-2024.10华中农业大学生命科学技术体育投注平台 生物工程博士后

2024.11-至今在线体育投注平台 副教授

研究课题：

1.国家自然科学基金青年科学基金项目（32300783）,靶向DLL3和γδ T细胞的双特异抗体对小细胞肺癌的免疫治疗活性研究，2024-2026，30万，在研，主持;

2.湖北省自然青年科学基金（2021CFB155）,靶向DLL3的新型CAR-T对小细胞肺癌的免疫治疗研究，2021-2023，8万，结题，主持；

3.中国博士后基金（2021M701338），表达DLL3双特异抗体的CAR-NK细胞对小细胞肺癌的免疫治疗活性研究，2021-2023，8万，结题，主持；

4.横向课题，TG3肝细胞株的大动物实验，2023-2025，30万，在研，主持。

5.湖北省博士后创新研究岗位，靶向DLL3的CAR-NK在小细胞肺癌中的抗肿瘤活性研究，2021，6万，结题，主持。

学术成果：

1.Xin Chen,Norhan Amar, Yuankui Zhu, Chunguang Wang, Chunjiao Xia, Xiaoqing Yang, Dongde Wu, Mingqian Feng^*. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.J Immunother Cancer. 2020, 8(1):e000785. (IF:13.86).

2.Xin Chen, Yanmin Chen, Rong Liang, Lanxin Xiang, Jingwen Li, Yuankui Zhu, Huixia He, Le Huang, Dianbao Zuo, Weihang Li, Xinjun Liang, Shuang Dong, Sheng Hu, Mitchell Ho^*, Mingqian Feng^*.Combination therapy of hepatocellular carcinoma by GPC3-targeted bispecific antibody and Irinotecan is potent in suppressing tumor growth in mice.Mol Cancer Ther. 2022, 21:149-158. (IF: 7.02).

3. Yuankui Zhu, Ke Wang, Linghe Yue, Dianbao Zuo, Junfeng Sheng, Zilong Zhao, Sheng Hu^*,Xin Chen^*, Mingqian Feng^*. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.Pharmacol Res.2024, 203:107186. (IF: 9.3).

4.Wenbo Chen^#,Xin Chen^#, Lei Yao^#, Jing Feng, Fengyue Li, Yuxin Shan, Linli Ren, Chenjian Zhuo, Mingqian Feng, Shan Zhong^*, Chunjiang He^*. A global view of altered ligand-receptor interactions in aging bone marrow based on single-cell sequencing.Comput Struct Biotec.2024, 23:2754-2762. (IF: 5.0).

5. Liu Yang^#,Xin Chen^#, Qian Wang, Yuankui Zhu, Changfa Wu, Xuqian Ma, Dianbao Zuo, Huixia He, Le Huang, Jingwen Li, Chunjiao Xia, Sheng Hu, Xiaoqing Yang^*, Mingqian Feng^*. Generation of TIM3 inhibitory single-domain antibodies (sdAbs) to boost the anti-tumor activity of CAR-T cells.Oncol Lett. 2021, 22:542. (IF: 3.11).

6.Wenbo Chen^#,Xin Chen^#, Zhenyu Zhao, Menglu Li, Shuang Dong, Sheng Hu, Xiaoyu Li, Mingqian Feng, Ke Chen, Shan Zhong^*, Chunjiang He^*.Pan-cancer identification of prognostic-associated metabolic pathways.Biology. 2023, 12:1129.(IF: 4.2).

7. Yuankui Zhu, Dianbao Zuo, Ke Wang, Sina Lan, Huixia He, Liu Chen,Xin Chen^*, Mingqian Feng^*. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.J Cancer Res Clin. 2023, 149(16):15027-15038. (IF: 3.6).